Carl, R. Alving
#132,583
Most Influential Person Now
Carl, R. Alving's AcademicInfluence.com Rankings
Carl, R. Alvingphilosophy Degrees
Philosophy
#6519
World Rank
#9565
Historical Rank
Logic
#3671
World Rank
#4867
Historical Rank
Carl, R. Alvingbiology Degrees
Biology
#8853
World Rank
#11989
Historical Rank
Immunology
#516
World Rank
#533
Historical Rank
Biochemistry
#1307
World Rank
#1427
Historical Rank
Download Badge
Philosophy Biology
Carl, R. Alving's Degrees
- PhD Biochemistry University of California, Berkeley
- Doctorate Medicine Johns Hopkins University
Why Is Carl, R. Alving Influential?
(Suggest an Edit or Addition)Carl, R. Alving's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. (2003) (401)
- Liposomes as carriers of antigens and adjuvants. (1991) (339)
- Transcutaneous immunization: A human vaccine delivery strategy using a patch (2000) (335)
- Complement activation by Cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. (1998) (326)
- Skin immunization made possible by cholera toxin (1998) (275)
- Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. (1978) (266)
- Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. (1992) (232)
- F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins (2003) (222)
- Adjuvants for human vaccines. (2012) (198)
- ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES (2002) (177)
- Complement-dependent damage to liposomes prepared from pure lipids and Forssman hapten. (1969) (177)
- Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge. (1998) (173)
- Animal Models of Complement-Mediated Hypersensitivity Reactions to Liposomes and Other Lipid-Based Nanoparticles (2007) (173)
- Safety and Immunogenicity of a Prototype Enterotoxigenic Escherichia coli Vaccine Administered Transcutaneously (2002) (162)
- Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. (1999) (159)
- Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants. (1993) (156)
- Delivery of liposome-encapsulated drugs to macrophages. (1983) (147)
- Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins as Antigens and Adjuvants (1999) (143)
- Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction. (2000) (140)
- Transcutaneous Immunization with Bacterial ADP-Ribosylating Exotoxins, Subunits, and Unrelated Adjuvants (2000) (138)
- Liposomes as Carriers of Peptide Antigens: Induction of Antibodies and Cytotoxic T Lymphocytes to Conjugated and Unconjugated Peptides (1995) (136)
- Design and selection of vaccine adjuvants: animal models and human trials. (2002) (131)
- Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. (2001) (128)
- HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. (1998) (122)
- Immunization with DNA through the skin. (2003) (121)
- Chemotherapy of leishmaniasis (2002) (116)
- Causative factors behind poloxamer 188 (Pluronic F68, Flocor)-induced complement activation in human sera. A protective role against poloxamer-mediated complement activation by elevated serum lipoprotein levels. (2004) (113)
- Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens. (1992) (107)
- Induction of Immune Responses in Mice and Monkeys to Ebola Virus after Immunization with Liposome-Encapsulated Irradiated Ebola Virus: Protection in Mice Requires CD4+ T Cells (2002) (106)
- Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. (2006) (106)
- Liposomes as carriers for vaccines. (1994) (103)
- Production of antibodies against phosphocholine, phosphatidylcholine, sphingomyelin, and lipid A by injection of liposomes containing lipid A. (1979) (102)
- Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines (2012) (100)
- Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys (1986) (99)
- A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge (1995) (96)
- Delivery of lipids and liposomal proteins to the cytoplasm and Golgi of antigen-presenting cells. mangala.rao@na.amedd.army.mil. (2000) (94)
- Induction of protective polyclonal antibodies by immunization with a Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. (1995) (93)
- Transcutaneous Immunization Using Colonization Factor and Heat-Labile Enterotoxin Induces Correlates of Protective Immunity for Enterotoxigenic Escherichia coli (2002) (92)
- Liposomes Containing Lipid A Serve as an Adjuvant for Induction of Antibody and Cytotoxic T-Cell Responses against RTS,S Malaria Antigen (1998) (92)
- Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes. (1996) (91)
- Improved therapy of experimental leishmaniasis by use of a liposome-encapsulated antimonial drug. (1978) (88)
- The Role of Complement Activation in Hypersensitivity to Pegylated Liposomal Doxorubicin (Doxil®) (2000) (86)
- Antibodies to cholesterol. (1988) (84)
- Interactions of plant lectins with glycolipids in liposomes (1977) (79)
- Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes (2009) (78)
- Liposomes as drug carriers in leishmaniasis and malaria. (1986) (78)
- Assembly of Human Immunodeficiency Virus (HIV) Antigens on Bacteriophage T4: a Novel In Vitro Approach To Construct Multicomponent HIV Vaccines (2006) (76)
- Liposomal adjuvants for human vaccines (2016) (75)
- Liposomes in leishmaniasis: therapeutic effects of antimonial drugs, 8-aminoquinolines, and tetracycline. (1980) (75)
- Effectiveness of liposomes as potential carriers of vaccines: applications to cholera toxin and human malaria sporozoite antigen. (1986) (75)
- Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages (1992) (74)
- Enhanced efficacy of liposome-encapsulated ribavirin against Rift Valley fever virus infection in mice (1985) (72)
- Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. (2013) (72)
- Antibodies to liposomes, phospholipids and phosphate esters. (1986) (71)
- Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. (1983) (71)
- Transcutaneous immunization: T cell responses and boosting of existing immunity. (2001) (71)
- Monoclonal Antibodies to Phosphatidylinositol Phosphate Neutralize Human Immunodeficiency Virus Type 1: Role of Phosphate-Binding Subsites (2006) (70)
- Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen. (1995) (70)
- Interaction of Sindbis virus with liposomal model membranes (1975) (70)
- Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. (2009) (68)
- Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes. (1977) (68)
- The interaction of liposomes with the complement system: in vitro and in vivo assays. (2003) (66)
- Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen (1988) (63)
- Phagocytosis of liposomes by macrophages: intracellular fate of liposomal malaria antigen. (1991) (63)
- Complement-dependent phagocytosis of liposomes by macrophages: suppressive effects of "stealth" lipids. (1991) (63)
- Adjuvants for vaccines to drugs of abuse and addiction. (2014) (62)
- Correlation between Lethal Toxin-Neutralizing Antibody Titers and Protection from Intranasal Challenge with Bacillus anthracis Ames Strain Spores in Mice after Transcutaneous Immunization with Recombinant Anthrax Protective Antigen (2006) (62)
- Liposomal Vaccines: Clinical Status and Immunological Presentation for Humoral and Cellular Immunity (1995) (61)
- In vitro binding of anthrax protective antigen on bacteriophage T4 capsid surface through Hoc-capsid interactions: a strategy for efficient display of large full-length proteins. (2006) (61)
- Multicomponent anthrax toxin display and delivery using bacteriophage T4. (2007) (61)
- Needle-Free Skin Patch Vaccination Method for Anthrax (2004) (60)
- Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. (1979) (59)
- Human Erythrocytes Selectively Bind and Enrich Infectious HIV-1 Virions (2009) (59)
- Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. (1994) (58)
- Advances in vaccine delivery: transcutaneous immunisation. (1999) (57)
- Antibody binding and complement fixation by a liposomal model membrane. (1969) (56)
- Differential immune responses to HIV-1 envelope protein induced by liposomal adjuvant formulations containing monophosphoryl lipid A with or without QS21. (2015) (56)
- Macrophages as targets for delivery of liposome-encapsulated antimicrobial agents (1988) (56)
- Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013. (2017) (56)
- Complement Activation During Hemorrhagic Shock and Resuscitation in Swine (2003) (56)
- Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers. (2015) (54)
- Principles of transcutaneous immunization using cholera toxin as an adjuvant. (1999) (54)
- Anaphylactoid reactions mediated by autoantibodies to cholesterol in miniature pigs. (1989) (53)
- Lipid A and liposomes containing lipid A as antigens and adjuvants. (2008) (51)
- Immunogenicity of liposomal malaria sporozoite antigen in monkeys: adjuvant effects of aluminium hydroxide and non-pyrogenic liposomal lipid A. (1989) (51)
- Natural antibodies against phospholipids and liposomes in humans. (1984) (50)
- Immune reactivities of antibodies against glycolipids--I. Properties of anti-galactocerebroside antibodies purified by a novel technique of affinity binding to liposomes. (1977) (50)
- Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. (1996) (50)
- A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse (2017) (49)
- Naturally occurring antibodies to cholesterol: a new theory of LDL cholesterol metabolism. (1999) (48)
- Antileishmanial activity of liposome-encapsulated meglumine antimonate in the dog. (1984) (48)
- Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. (1999) (48)
- Effect of the A and B protomers of choleragen on release of trapped glucose from liposomes containing or lacking ganglioside GM1. (1977) (47)
- Liposomes containing lipid A: a potent nontoxic adjuvant for a human malaria sporozoite vaccine. (1990) (47)
- Comparative properties of four galactosyl lipids as antigens in liposomes. (1974) (46)
- Cholesterol-dependent tetanolysin damage to liposomes. (1979) (46)
- Complement activation in vitro by the red cell substitute, liposome‐ encapsulated hemoglobin: mechanism of activation and inhibition by soluble complement receptor type 1 (1997) (46)
- Detection of liposomal cholesterol and monophosphoryl lipid A by QS-21 saponin and Limulus polyphemus amebocyte lysate. (2015) (44)
- Preparation and Use of Liposomes in Immunological Studies (1993) (44)
- Army Liposome Formulation (ALF) family of vaccine adjuvants (2020) (43)
- Sporozoite-induced malaria: therapeutic effects of glycolipids in liposomes. (1979) (43)
- Detection of antibodies to squalene: III. Naturally occurring antibodies to squalene in humans and mice. (2004) (43)
- Choleragen-mediated release of trapped glucose from liposomes containing ganglioside GM1. (1976) (42)
- Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants. (2017) (42)
- Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines. (1997) (42)
- TFH cells accumulate in mucosal tissues of humanized-DRAG mice and are highly permissive to HIV-1 (2015) (42)
- Induction and detection of antibodies to squalene. (2000) (42)
- HIV-1, lipid rafts, and antibodies to liposomes: implications for anti-viral-neutralizing antibodies (Review) (2006) (41)
- Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. (2014) (40)
- The use of liposome-encapsulated drugs in leishmaniasis (1979) (40)
- Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies. (1996) (40)
- Naturally occurring autoantibodies to cholesterol in humans. (1989) (40)
- Interactions of C-reactive protein and complement with liposomes. (1977) (40)
- Choleragen (cholera toxin): a bacterial lectin. (1979) (39)
- Induction of cytolytic and antibody responses using Plasmodium falciparum repeatless circumsporozoite protein encapsulated in liposomes. (1993) (39)
- Inhibition of lymphokine-induced macrophage microbicidal activity against Leishmania major by liposomes: characterization of the physicochemical requirements for liposome inhibition. (1986) (39)
- Liposomes as model membranes for ligand-receptor interactions: studies with choleragen and glycolipids. (1979) (39)
- Characterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines (2014) (38)
- Interactions of C-reactive protein and complement with liposomes. II. Influence of membrane composition. (1979) (38)
- Interaction of C-reactive protein with liposomes. III. Membrane requirements for binding. (1981) (38)
- Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor (2015) (38)
- Immune response to antigen adsorbed to aluminum hydroxide particles: Effects of co‐adsorption of ALF or ALFQ adjuvant to the aluminum‐antigen complex (2018) (37)
- Liposome spin immunoassay: a new sensitive method for detecting lipid substances in aqueous media. (1975) (37)
- Interactions of lipid a and liposome-associated lipid A with Limulus polyphemus amoebocytes (1983) (37)
- Anthrax Vaccine Antigen-Adjuvant Formulations Completely Protect New Zealand White Rabbits against Challenge with Bacillus anthracis Ames Strain Spores (2011) (37)
- LIGHT‐INDUCED LEAKAGE OF SPIN LABEL MARKER FROM LIPOSOMES IN THE PRESENCE OF PHOTOTOXIC PHENOTHIAZINES (1976) (37)
- Complement-dependent phagocytosis of liposomes. (1993) (36)
- Phosphate-binding specificities of monoclonal antibodies against phosphoinositides in liposomes. (1984) (36)
- Novel Adjuvant Strategies for Experimental Malaria and AIDS Vaccines (1993) (36)
- Immune Reactions of Lipids and Lipid Model Membranes (1977) (36)
- Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ). (2019) (35)
- Antibodies to squalene in US Navy Persian Gulf War veterans with chronic multisymptom illness. (2009) (35)
- Liposome-encapsulated HIV-1 Gag p24 containing lipid A induces effector CD4+ T-cells, memory CD8+ T-cells, and pro-inflammatory cytokines. (2009) (34)
- Influence of temperature on complement-dependent immune damage to liposomes. (1980) (34)
- Selection of an adjuvant for vaccination with the malaria antigen, MSA-2. (1997) (34)
- Oil-in-water liposomal emulsions for vaccine delivery. (2003) (34)
- Enhancement by lipid A of mucosal immunogenicity of liposome-associated cholera toxin. (1984) (33)
- Intracellular processing of liposome-encapsulated antigens by macrophages depends upon the antigen (1995) (33)
- Binding of diphtheria toxin to phospholipids in liposomes. (1980) (33)
- Macrophage activation for microbicidal activity against Leishmania major: inhibition of lymphokine activation by phosphatidylcholine-phosphatidylserine liposomes. (1985) (32)
- Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant (2017) (32)
- Lipid A from endotoxin: antigenic activities of purified fractions in liposomes. (1979) (32)
- Oil-in-water liposomal emulsions: characterization and potential use in vaccine delivery. (1999) (32)
- Influence of vesicle size on complement-dependent immune damage to liposomes. (1986) (32)
- Highly effective generic adjuvant systems for orphan or poverty-related vaccines. (2011) (32)
- Influence of membrane composition on the interaction of a human monoclonal "anti-Forssman" immunoglobulin with liposomes. (1974) (32)
- Visualization of peptides derived from liposome-encapsulated proteins in the trans-Golgi area of macrophages. (1997) (31)
- Liposomes in leishmaniasis: effects of parasite virulence on treatment of experimental leishmaniasis in hamsters. (1984) (30)
- Liposomes containing lipid A as a potent non-toxic adjuvant. (1992) (29)
- Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge (2020) (29)
- Localization of urinary lactosylceramide in cytoplasmic vesicles of renal tubular cells in homozygous familial hypercholesterolemia. (1983) (28)
- Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein (2004) (28)
- Complement-Dependent Phagocytosis of Liposomes: Suppression by “Stealth” Lipids (1992) (28)
- Cytotoxic T lymphocytes induced by liposomal antigens: mechanisms of immunological presentation. (1994) (28)
- The malaria merozoite surface: a 140,000 m.w. protein antigenically unrelated to other surface components on Plasmodium knowlesi merozoites. (1983) (28)
- Antibodies to lipid A: occurrence in humans. (1984) (28)
- Gangliosides elicit a T-cell independent antibody response. (1993) (28)
- Functional microtubules are required for antigen processing by macrophages and dendritic cells. (2004) (28)
- Membrane lipid composition modulates the binding specificity of a monoclonal antibody against liposomes. (1982) (28)
- HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development. (2013) (27)
- Selective cytotoxicity of tumor cells induced by liposomes containing plant phosphatidylinositol. (1983) (27)
- Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide. (2012) (27)
- Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research (2015) (27)
- Antibodies to phospholipids and liposomes: binding of antibodies to cells. (1987) (26)
- Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens. (2005) (25)
- Human Immunodeficiency Virus Type 1 Gag p24 Alters the Composition of Immunoproteasomes and Affects Antigen Presentation (2009) (23)
- [12] Complement-dependent phagocytosis of liposomes by macrophages (1987) (23)
- Anti-liposome antibodies induced by lipid A. I. Influence of ceramide, glycosphingolipids, and phosphocholine on complement damage. (1981) (23)
- Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate. (1987) (23)
- Complement-mediated acute effects of liposome-encapsulated hemoglobin. (1999) (23)
- Suppression of phagocytic function and phospholipid metabolism in macrophages by phosphatidylinositol liposomes. (1984) (22)
- Cell Type-Specific Proteasomal Processing of HIV-1 Gag-p24 Results in an Altered Epitope Repertoire (2010) (22)
- Therapeutic Potential of Liposomes as Carriers in Leishmaniasis, Malaria, and Vaccines (1982) (22)
- Liposomes as vehicles for vaccines. (1980) (22)
- 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. (2008) (22)
- Complement activation and thromboxane secretion by liposome-encapsulated hemoglobin in rats in vivo: inhibition by soluble complement receptor type 1. (1997) (22)
- Polymeric biodegradable lipospheres™ as vaccine delivery systems (1992) (21)
- The preparation and properties of liposomes in the LA and LAC states. (1971) (21)
- Synthesis and immunological effects of heroin vaccines. (2014) (21)
- Lipospheres as a Vaccine Carrier System: Effects of Size, Charge, and Phospholipid Composition (1992) (21)
- Heterogeneity of lipid A. (1984) (21)
- Antibodies to Lipids and Liposomes: Immunology and Safety (2006) (21)
- Studies on the Topography of the Catalytic Site of Acetylcholinesterase Using Polyclonal and Monoclonal Antibodies (1990) (21)
- Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A. (1995) (21)
- Immune reactivities of antibodies against glycolipids--II. Comparative properties, using liposomes, of purified antibodies against mono-, di- and trihexosyl ceramide haptens. (1977) (20)
- Liposome‐stabilized oil‐in‐water emulsions as adjuvants: Increased emulsion stability promotes induction of cytotoxic T lymphocytes against an HIV envelope antigen (2004) (20)
- Effects of lipid A and liposomes containing lipid A on platelet and fibrinogen production in rabbits. (1980) (20)
- Immune Reactivities of Antibodies against Glycolipids: Natural Antibodies (1980) (20)
- Designing the epitope flanking regions for optimal generation of CTL epitopes. (2014) (19)
- Effect of cytokines on Siglec-1 and HIV-1 entry in monocyte–derived macrophages: the importance of HIV-1 envelope V1V2 region (2015) (19)
- Influence of glycolipids on immune reactions of phospholipid antigens in liposomes. (1985) (19)
- Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. (1991) (19)
- Complement activation by liposome-encapsulated hemoglobin in vitro: the role of endotoxin contamination. (1995) (19)
- Antibodies induced by liposomal protein exhibit dual binding to protein and lipid epitopes. (2008) (19)
- Calcium modulation of monoclonal antibody binding to phosphatidylinositol phosphate. (2007) (19)
- Liposome-Encapsulated Human Immunodeficiency Virus-1 gp120 Induces Potent V1V2-Specific Antibodies in Humans (2018) (18)
- Abnormal lipid composition of the red cell membrane in congenital dyserythropoietic anemia type II (HEMPAS). (1975) (18)
- Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants. (1998) (18)
- Inhibitory effects of gangliosides on immune reactions of antibodies to neutral glycolipids in liposomes. (1986) (18)
- Designing a Soluble Near Full-length HIV-1 gp41 Trimer* (2012) (18)
- HIV-1 Envelope Resistance to Proteasomal Cleavage: Implications for Vaccine Induced Immune Responses (2012) (18)
- Antibodies against liposomes in normal and immune-defective mice. (1982) (18)
- Suppression of cytotoxicity of diphtheria toxin by monoclonal antibodies against phosphatidylinositol phosphate. (1982) (18)
- Antibodies to liposomal phosphatidylserine and phosphatidic acid. (1990) (18)
- Liposomal subunit vaccines: effects of lipid A and aluminum hydroxide on immunogenicity. (1996) (18)
- Effects on the murine mononuclear phagocyte system of chronic administration of liposomes containing cytotoxic drug or lipid A compared with empty liposomes. (1987) (18)
- A simple nonradioactive method for the determination of the binding affinities of antibodies induced by hapten bioconjugates for drugs of abuse (2015) (17)
- Modulation of immunoproteasome subunits by liposomal lipid A. (2008) (17)
- Antibodies reactive with liposomal phospholipids are produced during experimental Trypanosoma rhodesiense infections in rabbits. (1983) (17)
- Antibodies to cholesterol: biological implications of antibodies to lipids. (1996) (17)
- An anti-phosphoinositide-specific monoclonal antibody that neutralizes HIV-1 infection of human monocyte-derived macrophages. (2012) (16)
- The influence of retinal on complement-dependent immune damage to liposomes (1974) (16)
- Platelets and Erythrocyte-Bound Platelets Bind Infectious HIV-1 in Plasma of Chronically Infected Patients (2013) (16)
- Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits. (2009) (16)
- Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21 (2019) (15)
- Potentiation of liposome-induced complement activation by surface-bound albumin. (2002) (15)
- Mitogenic activities of lipid A and liposome-associated lipid A: effects of epitope density. (1984) (15)
- Antibodies to liposomal phosphatidylcholine and phosphatidylsulfocholine. (1990) (14)
- Cross-reactions of nucleic acids with monoclonal antibodies to phosphatidylinositol phosphate and cholesterol. (1989) (14)
- Summary: Adjuvants/Clinical Trials Working Group. (1992) (14)
- Depletion of cellular cholesterol interferes with intracellular trafficking of liposome‐encapsulated ovalbumin (2003) (13)
- Proteasome inhibitors block the entry of liposome-encapsulated antigens into the classical MHC class I pathway. (2000) (13)
- Membrane-specific antibodies induced by liposomes can simultaneously bind to HIV-1 protein, peptide, and membrane lipid epitopes† (2008) (13)
- The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies. (2010) (13)
- Heterogeneity of lipid A: comparison of lipid A types from different gram-negative bacteria (1984) (13)
- Trafficking of liposomal antigen to the trans-Golgi of murine macrophages requires both liposomal lipid and liposomal protein. (1999) (13)
- Complement-Dependent Shock and Tissue Damage Induced by Intravenous Injection of Cholesterol-Enriched Liposomes in Rats (2003) (13)
- Liposomal chemotherapy in visceral leishmaniasis: An ultrastructural study of an intracellular pathway (2004) (13)
- Metabolic fate of liposomal phosphatidylinositol in murine tumor cells: implications for the mechanism of tumor cell cytotoxicity. (1985) (13)
- Induction and detection of antibodies to squalene. II. Optimization of the assay for murine antibodies. (2002) (13)
- Life-Long Administration of Liposomes and Lipid A in Mice: Effects on Longevity, Antibodies to Liposomes, and Terminal Histopathological Patterns (1988) (13)
- Vaccines to Treat Drug Addiction (2004) (12)
- Liposomes as Adjuvants for Vaccines (1997) (12)
- Human Primary Macrophages Derived In Vitro from Circulating Monocytes Comprise Adherent and Non-Adherent Subsets with Differential Expression of Siglec-1 and CD4 and Permissiveness to HIV-1 Infection (2017) (12)
- Adjuvants for HIV vaccines (2016) (12)
- Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria (2021) (12)
- Vitamin A in liposomes. Inhibition of complement binding and alteration of membrane structure. (1975) (12)
- Inhibition of HIV-1 infection of peripheral blood mononuclear cells by a monoclonal antibody that binds to phosphoinositides and induces secretion of β-chemokines (2010) (11)
- Binding of choleragen and anti-ganglioside antibodies to gangliosides incorporated into preformed liposomes. (1983) (11)
- Differential inhibition of macrophage microbicidal activity by liposomes (1985) (11)
- Specific binding of concanavalin A to free inositol and liposomes containing phosphatidylinositol. (1985) (11)
- A rapid solution-based method for determining the affinity of heroin hapten-induced antibodies to heroin, its metabolites, and other opioids (2018) (10)
- Forssman-containing liposomes: complement-dependent damage due to interaction with a monoclonal IgM. (1974) (10)
- Infection of human peripheral blood mononuclear cells by erythrocyte-bound HIV-1: effects of antibodies and complement. (2011) (10)
- Cerebrovascular Involvement in Liposome—Induced Cardiopulmonary Distress in Pigs (2005) (10)
- Lipid A fractions analyzed by a technique involving thin-layer chromatography and enzyme-linked immunosorbent assay. (1984) (10)
- Saturated phospholipids are required for nano- to micron-size transformation of cholesterol-containing liposomes upon QS21 addition (2018) (9)
- Liposome Formulations as Adjuvants for Vaccines. (2020) (9)
- Protective prophylactic immunity against intranasal ricin challenge induced by liposomal ricin a subunit (1996) (9)
- Complement-dependent immune damage to liposomes containing gangliosides. (1985) (9)
- Lipospheres for Vaccine Delivery (2020) (9)
- Practical Considerations for the Development of Vaccines Against Drugs of Abuse (2016) (8)
- Inhibition of interferon γ-induced macrophage microbicidal activity against Leishmania major by liposomes: Inhibition is dependent upon composition of phospholipid headgroups and fatty acids (1989) (8)
- Liposome techniques in cell biology (1987) (8)
- Immunologic Presentation of Liposomal Antigens (1993) (8)
- Ganglioside GM1 Binding Peptides: A Potential Adjuvant for Transcutaneous Immunization (2009) (8)
- Immune Damage to Liposomes Containing Lipids from Schistosoma mansoni Worms (1974) (8)
- Liposomes in Leishmaniasis: The Lysosome Connection (1984) (7)
- Liposome-induced and complement-mediated cardiopulmonary distress in pigs as a model of pseudo-allergic reactions to liposomal drugs (1998) (7)
- Modulation of phosphatidylinositol turnover by liposomes containing phosphatidylinositol. (1987) (7)
- Mitogenic response of lymphocytes from C3H/HeJ mice in the presence of lipid A and lipid A fractions. (1984) (6)
- Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques (2021) (6)
- Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A. (2011) (6)
- Liposomes as Carriers of Vaccines (1989) (6)
- IN VIVO DEMYELINATION PRODUCED BY PURIFIED ANTIBODIES TO GALACTOCEREBROSIDE: 113 (1979) (6)
- CHAPTER 2.1 – Class I presentation of liposomal antigens (1998) (6)
- Prostaglandin and thromboxane in liposomes: suppression of the primary immune response to liposomal antigens. (1989) (5)
- Erratum for Ramakrishnan et al., “Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21” (2019) (5)
- Complement-dependent phagocytosis of liposomes by macrophages. (1987) (5)
- Liposomes as carriers for a human malaria sporozoite vaccine. (1988) (5)
- Liposomes as Carriers of Vaccines: Development of a Liposomal Malaria Vaccine (1989) (5)
- Rheoencephalographic evidence of complement activation-related cerebrovascular changes in pigs (2005) (5)
- Design and selection of vaccine adjuvants: principles and practice (2005) (5)
- ATP specifically bound as a hapten to a monoclonal anti-phospholipid antibody retains phosphate donor activity. (1993) (5)
- Emulsification of Liposomes with Incomplete Freund's Adjuvant: Stability of the Liposomes and the Emulsion (1998) (5)
- Effects of aluminium adjuvant compounds, tweens, and spans on the stability of liposome permeability (1996) (5)
- CHAPTER 2.7 – Theoretical basis for development of liposomes as carriers of vaccines (1998) (5)
- Re: Antibodies to squalene in Gulf War Syndrome. (2000) (5)
- Antibodies to liposomes, phospholipids, and cholesterol: implications for autoimmunity, atherosclerosis, and aging. (1990) (4)
- Vaccination Against Cholesterol: Immunologic Modulation of Diet-Induced Hypercholesterolemia and Atherosclerosis in Rabbits. (1995) (4)
- Synthesis of Hapten-Protein Conjugate Vaccines with Reproducible Hapten Densities. (2016) (4)
- Transcutaneous immunization using SLA or rLACK skews the immune response towards a Th1 profile but fails to protect BALB/c mice against a Leishmania major challenge. (2019) (4)
- The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization. (2010) (4)
- Trafficking of liposomal antigens to the trans-Golgi complex in macrophages. (2003) (4)
- Liposomes as Safe Carriers of Drugs and Vaccines (1992) (3)
- Correction for Ramakrishnan et al., “Enhanced Immunogenicity and Protective Efficacy of a Campylobacter jejuni Conjugate Vaccine Coadministered with Liposomes Containing Monophosphoryl Lipid A and QS-21” (2019) (3)
- LIPOSOMAL VACCINE ADJUVANT FORMULATIONS (2016) (3)
- Radioprotective effects of lipid A, liposomes, and liposomes containing lipid A in mice. (1987) (3)
- Walter Reed Army Institute of Research (WRAIR): Fifty Years of Achievements That Impact Science and Society (2020) (3)
- Conserved Influenza Hemagglutinin, Neuraminidase and Matrix Peptides Adjuvanted with ALFQ Induce Broadly Neutralizing Antibodies (2021) (3)
- Liposomes as Drug Carriers for Treatment of Leishmaniasis (1986) (3)
- Phosphatidylinositol liposomes opsonized by concanavalin A stimulate phosphatidylinositol turnover in macrophages. (1986) (3)
- Tumoricidal effects of liposomes containing phosphatidylinositol or phosphatidylcholine. (1987) (3)
- Interaction ofSindbis Virus withLiposomal ModelMembranes (1975) (3)
- Cholesterol-Dependent Nonimmune Human Complement Activation Resulting in Damage to Liposomes (1976) (2)
- Requirements for binding. (1981) (2)
- Complement Activation by Liposome-CRP Complexes: Influence of Membrane Composition (1978) (2)
- Toxic effects of antileishmanial reverse-phase evaporation liposomes containing dicetyl phosphate in monkeys (1995) (2)
- Liposomes as Vehicles for Vaccines: Intracellular Fate of Liposomal Antigen in Macrophages (1991) (2)
- Interactions of Liposomes with Complement Leading to Adverse Reactions . . . . . . . . . . . . . . . . . . . . . . . . . . . . and Rolf Bu¨nger (2006) (2)
- Chapter 9 – Vaccine Adjuvants* (2009) (2)
- Lipid A and Liposomes Containing Lipid A as Adjuvants for Vaccines. Chapter 18 (1993) (2)
- P-D8 HIV-1 Envelope Variable Loop V2 and V3 Peptides Inhibit a4b7 Integrin Receptor Binding to MAdCAM-1 (2014) (2)
- Hapten selection for heroin vaccines (2015) (2)
- Induction of protective polyclonal antibodies by immunization with Plasmodium yoelii circumsporozoite protein multiple antigen peptide vaccine. (1995) (2)
- Therapyofleishmaniasis: Superior efficacies ofliposome- encapsulated drugs (antimonial compounds/phospholipids/model membranes/parasites) (1978) (2)
- Determination of human serum complement activation by commercial, clinical and chemically modified block copolymer poloxamer 188 (2002) (1)
- Oral Presentations—Abstracts (2003) (1)
- Inhibition of interferon gamma-induced macrophage microbicidal activity against Leishmania major by liposomes: inhibition is dependent upon composition of phospholipid headgroups and fatty acids. (1989) (1)
- Interactions of lectins with glycolipids in liposomes. (1977) (1)
- Variation of complement activation in human serum by Poloxamer 188 (Pluronic-F68) (2001) (1)
- COMPLEMENT ACTIVATION - RELATED HYPERSENSITIVITY REACTIONS CAUSED BY PEGYLATED LIPOSOMES SEARCH FOR AN ALTERNATIVE LONG-CIRCULATING LIPOSOME FORMULATION WITHOUT COMPLEMENT ACTIVATION (2003) (1)
- Macrophage Activation by Liposomal Lipid A: Implications for Vaccines (1996) (1)
- Liposomes containing glucosyl ceramide specifically bind T4 bacteriophage: a self-assembling nanocarrier formulation (2011) (1)
- Demetrios Papahadjopoulos and Liposomes: From Art to Science (1995) (1)
- Liposomes and macrophage functions: Discussion (1992) (1)
- Cardiovascular effects of liposomes in miniature pigs: Endogenous release of thromboxane (1988) (1)
- Army liposome formulation containing QS-21 render human monocyte-derived macrophages less permissive to HIV-1 infection by upregulating APOBEC3A (2022) (1)
- Hypersensitivity to taxol and doxil: Experimental and clinical evidence for a causal role of complement activation (2000) (1)
- Interactions of Infectious HIV-1 Virions with Erythrocytes: Implications for HIV-1 Pathogenesis and Infectivity (2011) (1)
- Complement Inhibitor APT070 Dramatically Reduces the Need for Resuscitation and Improves Survival in Controlled Isobaric Rat Hemorrhage Model (2004) (1)
- Effect of Preexisting Immunity to Tetanus Toxoid on the Efficacy of Tetanus Toxoid-Conjugated Heroin Vaccine in Mice (2021) (0)
- Immunized with Oligomeric gp160 Respiratory Tracts of Mice Intranasally HIV-1 Neutralizing Antibodies in the Genital and (1998) (0)
- Complement activation by the non-ionic surfactant poloxamer 188 and a regulatory role for HDL and LDL. (2004) (0)
- Induction of linear and conformational V2-specific antibodies using HIV-1 gp145 clade B envelope protein as the immunogen (P4505) (2013) (0)
- Lethal Mucosal Toxin Challenge with Cholera Toxin Protects Mice Against Cutting Edge: Transcutaneous Immunization (1998) (0)
- MILITARY MEDICAL HISTORY (2021) (0)
- Isolation and Purification of Proteasomes from Primary Cells (2014) (0)
- Drug Delivery Systems Including Liposomes as Carriers (1989) (0)
- Policing function of complement: through the body with gun and camera. (1997) (0)
- Safety , toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein ( FMP 013 ) with the adjuvant army liposome formulation containing (2019) (0)
- Antibodies to Lipids and Lipid Membranes: Reactions with Phosphatidylcholine, Cholesterol, Liposomes and Bromelin-Treated Erythrocytes (2020) (0)
- COMPLEMENT ACnVAlION BY LIPOSOMK-ENCAPSULATED HEMOGLOBIN JBV VITRO: TH» »OLE OF ENDOTOXIN CONTAMINATION (1998) (0)
- Similarities and differences of chemical compositions and physical and functional properties of adjuvant system 01 and army liposome formulation with QS21 (2023) (0)
- Effects of a phospholipase A/sub 2/ inhibitor on uptake and toxicity of liposomes containing plant phosphatidylinositol (1986) (0)
- Letter to the editor (multiple letters) (1999) (0)
- Liposomes and macrophage functions (1992) (0)
- Malaria transmission-blocking conjugate vaccine in ALFQ adjuvant induces durable functional immune responses in rhesus macaques (2021) (0)
- Phospholipid Compositions and Their Effective Use as Anti-Tumor Agents. (1986) (0)
- Efficacy of liposomes as adjuvants and as carriers for a synthetic malaria sporozoite antigen (1988) (0)
- Medikamentpraeparatet with reduced toxicity (1985) (0)
- Henry M Jackson Foundation for the Advancement of Military Medicine, 1600 East Gude Drive, (2010) (0)
- I~emoglobin: the role of natural anti-phospholipid antibodies (2003) (0)
- Early Events in the Selective Cytotoxicity to Tumor Cells Induced by Liposomes Containing Plant Phosphatidylinositol (1985) (0)
- Choleragen ( cholera toxin ) : A bacterial lectin ( ganglioside GMI / agglutination / liposomes ) (0)
- CLINICAL TRIALS OF OncoVax-PTM (PROSTATE CANCER VACCINE) IN PATIENTS WITH PROSTATE CANCER (1997) (0)
- Complement consumption, hemolysis and thromboxane secretion following injection of hemoglobin-containing liposomes in rats (1994) (0)
- Heroin-HIV-1 (H2) vaccine: induction of dual immunologic effects with a heroin hapten-conjugate and an HIV-1 envelope V2 peptide with liposomal lipid A as an adjuvant (2017) (0)
- Liposomal formulation improved. (1996) (0)
- Mitogenic and limulus activities of lipid a and lipid a fractions in liposomes (1981) (0)
- Modulation of Cellular Phosphatidylinositol Turnover by Exogenous Phosphatidylinositol. (1987) (0)
- Gordon Research Conference on Drug Carriers in Biology and Medicine, 12-16 July 1982, Plymouth, New Hampshire. (1983) (0)
- Liposomes : Role of Complement and Inhibition by Soluble CR 1 and AntiC 5 a Hemoglobin in Pigs : A Model for Pseudoallergic Cardiopulmonary Reactions to Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated (1999) (0)
- Antibody responses induced to the C1 region of HIV-1 gp120 in acute HIV-1 infection and after vaccination (2017) (0)
- Synthetic 30–50 peptide fragment of cholera toxin β chain is a possible carrier for peptide antigens (1985) (0)
- Improved Therapy of Leishmaniasis by Encapsulation of Antimonial Drug in Biodegradable Artificial Phospholipid Vesicles (Liposomes) (1978) (0)
- Cell Type-Specific Proteasomal Processing of HIV-1 Gag-p24 Results in an Altered Epitope Repertoire (cid:1) (2011) (0)
- Formulation liposomale amelioree (1996) (0)
- hypotension-bradycardia paradox revisited When the heart is stopped for good: (2015) (0)
- Platelet and Fibrinogen Production: Effect of Lipid a and Liposomes (1979) (0)
- Reduction de la toxicite de certains medicaments (1984) (0)
- COMPLEMENT ACTIVATION BY LBPOSOME-ENCAPSüLATED HEMOGLOBIN IN VITRO : THE » OLE OF ENDOTOXIN CONTAMINATION (1999) (0)
- Commentary: Some Thoughts on an International Liposome Society (1999) (0)
- DRUG PREPARATIONS OF REDUCED TOXCITY 75 Inventors : (2017) (0)
- Adjuvants and Novel Vaccines: Conference Summary (1995) (0)
- Acknowledgement to Referees (2015) (0)
- Development of a combination heroin-HIV vaccine (2017) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Carl, R. Alving?
Carl, R. Alving is affiliated with the following schools:
